LDHA and neoplasm: To achieve potent anti-tumor immunity, a redox-responsive nano-assembly (R-mPDV/PDV/DOX/siL)-based immunochemotherapy regimen was developed, which integrates a combined strategy of inhibiting cytokine-mediated MDSC recruitment through LDHA silencing and enhancing tumor immunogenicity through anthracycline (DOX)-induced immunogenic cell death effects.